跳转至内容
Merck
CN

35485

Supelco

2,4′-DDD

PESTANAL®, analytical standard

别名:

1-(2-氯苯基)-1-(4-氯苯基)-2,2-二氯乙烷, o,p′-DDD, 氯苯二氯乙烷, 米托坦

登录查看公司和协议定价

关于此项目

线性分子式:
(ClC6H4)2CHCHCl2
CAS Number:
分子量:
320.04
Beilstein:
2056007
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

analytical standard

质量水平

产品线

PESTANAL®

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

agriculture
environmental

包装形式

neat

SMILES字符串

ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl

InChI

1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

InChI key

JWBOIMRXGHLCPP-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).

应用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

法律信息

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Health hazard

警示用语:

Warning

危险声明

危险分类

Carc. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Martin Fassnacht et al.
The Lancet. Oncology, 16(4), 426-435 (2015-03-22)
Adrenocortical carcinoma is a rare, aggressive cancer for which few treatment options are available. Linsitinib (OSI-906) is a potent, oral small molecule inhibitor of both IGF-1R and the insulin receptor, which has shown acceptable tolerability and preliminary evidence of anti-tumour
Richard A Feelders et al.
The Journal of clinical endocrinology and metabolism, 98(2), 425-438 (2013-01-25)
Cushing's disease (CD) is associated with serious morbidity and, when suboptimally treated, an increased mortality. Although surgery is the first-line treatment modality for CD, hypercortisolism persists or recurs in an important subset of patients. Considering the deleterious effects of uncontrolled

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持